Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects.
Background: Analytical data suggesting that immunoglobulin given intramuscularly (IGIM) may have reduced protection against hepatitis A virus (HAV) infection led to an update in the recommended IGIM dose (0.2 ml/kg).Methods: This prospective, open-label, single-arm clinical study evaluated whether a...
| Publicado en: | Advances in Therapy Vol. 37; no. 5; pp. 2373 - 2390 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Springer Nature
May2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |